文献速递中医内科中药与中成药合理使用

口服中成药治疗COVID-19疗效与安全性的快速系统评价与Meta分析

Therapeutic effects and safety of oral Chinese patent medicine for COVID-19: A rapid systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · Complement Ther Med · 2021-06-06

该快速系统评价与Meta分析纳入7项RCT共1079例COVID-19患者,评估口服中成药联合常规西药对比单用常规西药的疗效与安全性。结果显示联合治疗可提高治愈率、降低恶化率,并缩短发热、咳嗽、乏力持续时间,但证据确定性低或极低,所有试验总体偏倚风险高。

要点

  • 口服中成药联合常规西药可提高治愈率(RR=1.20,95%CI 1.04-1.38)。
  • 联合治疗可降低恶化率(RR=0.50,95%CI 0.29-0.85)。
  • 证据确定性低或极低,所有试验总体偏倚风险高。

核心结论

  • 低或极低确定性证据表明口服中成药对非重症COVID-19患者可能具有附加潜在治疗效应。
  • 上述发现需设计良好、样本量充足的临床试验进一步证实。

研究设计与样本

  • 快速系统评价与Meta分析,纳入7项随机对照试验(RCT),共1079例参与者。
  • 使用Cochrane Risk of Bias Tool 2.0评估偏倚风险,RevMan 5.4进行数据分析,在线GRADEpro工具评估证据确定性。

主要发现

  • 与单用常规西药相比,口服中成药联合常规西药提高治愈率(RR=1.20,95%CI 1.04-1.38,涉及LHQW和TJQW)。
  • 联合治疗降低恶化率(RR=0.50,95%CI 0.29-0.85,涉及LHQW、JHQG、LHQK和TJQW)。
  • 联合口服中成药缩短发热、咳嗽和乏力持续时间,提高咳嗽和乏力恢复率,并提高胸部CT表现的改善率和恢复率。
  • 不同中成药对同一COVID-19结局的治疗效应存在差异。
  • TJQW和LHQG似乎不增加不良事件风险,但JHQG可能导致轻度腹泻。

关键数值与推荐

  • 治愈率:RR=1.20,95%CI 1.04-1.38(涉及LHQW和TJQW)。
  • 恶化率:RR=0.50,95%CI 0.29-0.85(涉及LHQW、JHQG、LHQK和TJQW)。
  • 所有纳入试验的总体偏倚风险评估为高偏倚风险。
  • 证据确定性评估为低或极低。

临床怎么用

  • 对于非重症COVID-19患者,可考虑在常规西药治疗基础上加用口服中成药(如LHQW、JHQG、LHQK、TJQW)。
  • 使用JHQG时需注意可能引起轻度腹泻。
  • 临床决策应结合低或极低证据确定性的现状,并关注不同中成药效应的差异。

局限性

  • 所有纳入试验总体偏倚风险评估为高偏倚风险。
  • 证据确定性为低或极低。
  • 需要设计良好、样本量充足的临床试验进一步证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chinese patent medicine (CPM) is an indispensable part of traditional Chinese medicine. Coronavirus Disease 2019 (COVID-19) manifests is an acute respiratory infectious disease. This systematic review aimed to evaluate the therapeutic effects and safety of oral CPM for COVID-19. METHODS: We included randomized controlled trials (RCTs) that tested oral CPM for the treatment of COVID-19 identified from publications in CNKI, Wanfang, VIP, Web of Science, SinoMed, PubMed, Embase, BioRxiv, MedRxiv and arXiv before November 2nd, 2020. The risk of bias for each trial was assessed using the Cochrane Risk of Bias Tool 2.0. RevMan 5.4 software was used for data analyses. The certainty of the evidence was assessed using the online GRADEpro tool. RESULTS: Seven RCTs including 1079 participants were identified. The overall bias was assessed as "-high risk of bias" for all included trials. Oral CPM investigated were: Lianhua Qingwen capsule/granules (LHQW), Jinhua Qinggan granules (JHQG), Huoxiang Zhengqi dripping pills (HXZQ), Toujie Quwen granules (TJQW) and Lianhua Qingke granules (LHQK). Compared with conventional western therapy alone for people with COVID-19: regarding the main outcomes, the results showed that oral CPM combined with conventional western therapy improved cure rate (RR = 1.20, 95 % CI 1.04-1.38, involving LHQW and TJQW), reduced aggravation rate (RR = 0.50, 95 % CI 0.29 - 0.85, involving LHQW, JHQG, LHQK and TJQW); with regard to additional outcomes, the results showed that add-on oral CPM shortened the duration of fever, cough and fatigue, improved the recovery rate of cough and fatigue, and increased the improvement and recovery rate of chest CT manifestations. There were some differences in therapeutic effects among various CPMs for the same COVID-19 outcome. The use of TJQW and LHQG appeared not to increase the risk of adverse events, but JHQG may cause mild diarrhea. CONCLUSION: Low-certainty or very low-certainty evidence demonstrated that oral CPM may have add-on potential therapeutic effects for patients with non-serious COVID-19. These findings need to be further confirmed by well-designed clinical trials with adequate sample sizes.

来源:Complement Ther Med,查看原文。版权归原作者所有。

引用

  1. Liang SB, Fang M, Liang CH, et al. Therapeutic effects and safety of oral Chinese patent medicine for COVID-19: A rapid systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2021. PMID: 34091029. doi:10.1016/j.ctim.2021.102744

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。